http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 06:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html <p align="justify">                                                                         </p> <p align="center"><b>Urteste S.A. Receives U.S. Patent for the Panuri Test</b><br/></p> <p align="justify"><b>Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Receives+U.S.+Patent+for+the+Panuri+Test/26716333.html Wed, 01 Jul 2026 06:07:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Press+Releases/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html <p align="center"><b>Urteste S.A. enrolls the first patient in the Panuri test clinical study</b><br/></p> <p align="justify"><b>Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to schedule and within budget.</b></p> <p align="justify">Panuri is Urteste’s priority project and involves the development http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+enrolls+the+first+patient+in+the+Panuri+test+clinical+study/26627869.html Wed, 10 Jun 2026 09:20:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Press+Releases/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html <p align="center"><strong>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</strong></p> <p>Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025.</p> http://www.streetinsider.com/Globe+Newswire/Urteste+S.A.+Completes+Development+of+Panuri+Test+%E2%80%93+Company+Plans+to+Launch+Clinical+Study+in+Q3+2025/25073414.html Mon, 21 Jul 2025 08:14:00 -0400 A.60012005 O.41177255 O.54272833 URT URT http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html <p align="justify">27 MARCH 2025                PRESS RELEASE</p> <p align="justify"><strong>Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025</strong><br/></p> <p align="justify">Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in innovative technology for cancer detection through unique urine sample analysis, plans to initiate clinical trials in the European Union in Q3 2025 for the Panuri project—a diagnostic test for pancreatic cancer. In the coming weeks, Urteste will announce a tender to select a Contract Research Organization (CRO) to conduct the clinical trials. Additionally, the company is scheduled to http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html Thu, 27 Mar 2025 11:21:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html <p align="justify">27 MARCH 2025                PRESS RELEASE</p> <p align="justify"><strong>Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025</strong><br/></p> <p align="justify">Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in innovative technology for cancer detection through unique urine sample analysis, plans to initiate clinical trials in the European Union in Q3 2025 for the Panuri project—a diagnostic test for pancreatic cancer. In the coming weeks, Urteste will announce a tender to select a Contract Research Organization (CRO) to conduct the clinical trials. Additionally, the company is scheduled to http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html Thu, 27 Mar 2025 11:21:00 -0400 O.41177255 URT URT http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html <p align="justify">27 MARCH 2025                PRESS RELEASE</p> <p align="justify"><strong>Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025</strong><br/></p> <p align="justify">Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in innovative technology for cancer detection through unique urine sample analysis, plans to initiate clinical trials in the European Union in Q3 2025 for the Panuri project—a diagnostic test for pancreatic cancer. In the coming weeks, Urteste will announce a tender to select a Contract Research Organization (CRO) to conduct the clinical trials. Additionally, the company is scheduled to http://www.streetinsider.com/Press+Releases/Urteste+plans+to+start+clinical+trials+for+its+pancreatic+cancer+test+in+Europe+in+Q3+2025/24557488.html Thu, 27 Mar 2025 11:21:00 -0400 O.41177255 URT URT